Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2006-11-28
Berch, Mark (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S254000
Reexamination Certificate
active
07141575
ABSTRACT:
The use of a compound of formula (I): wherein R1is selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4CONR5, NR4CONR5R6,NR4CO2R7and NR4SO2R7; R2is selected from aryl attached via an unsaturated carbon; R3is selected from H, alkyl, COR5, CO2R7, CONR5R6, CONR4NR5R6and SO2R7; R4, R5and R6are independently selected from H, alkyl and aryl or where R5and R6are in an NR5R6group, R5and R6may be linked to form a heterocyclic group, or where R4, R5and R6are in a (CONR4NR5R6) group, R4and R5may be linked to form a heterocyclic group; and R7is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se
REFERENCES:
patent: 4739053 (1988-04-01), Albert et al.
patent: 5204353 (1993-04-01), Meier
patent: 5747496 (1998-05-01), Cox et al.
patent: 6107301 (2000-08-01), Aldrich et al.
patent: 6197788 (2001-03-01), Fletcher et al.
patent: 6583156 (2003-06-01), Gillespie et al.
patent: 6608085 (2003-08-01), Gillespie et al.
patent: 6787541 (2004-09-01), Gillespie et al.
patent: 1 221 444 (2002-07-01), None
patent: 1 300 147 (2003-04-01), None
patent: 56/131586 (1981-10-01), None
patent: 56/131587 (1981-10-01), None
patent: 59/062595 (1984-04-01), None
patent: 60/140335 (1985-07-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/21617 (1999-05-01), None
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Kulisevsky, Jaime; Barbanoj, Manel; Gironell, Alexandre; Antonijoan, Rosa; Casas, Miquel; Pascual-Sedano, Berta, Clinical Neuropharmacology. 25(1):25-31, Jan./Feb. 2002, abstract only.
Morelli, Micaela, Experimental Neurology, 184, 20-23, 2003.
Tuite, Paul et al, Expert. Opin. Investig. Drugs, 12, 1335-1352, 2003.
Bibbiani, F. et al, Experimental Neurology, 184, 285-294, 2003.
Spiros Konitsiotis, Expert. Opin. Investig. Drugs, 14, 377-392 2005.
Anonymous, Drug and Therapeutic Bulletin, 35, pp. 36-40, 1999.
LeWitt, Peter A., Pharmacotherapy, 20, pp. 26S-32S, 2000.
Loscher W.,.Epilepsy Res. Jun. 2002;50(1-2):105-23.
Jennifer L. Hellier, Peter R. Patrylo, Ping Dou, Michelle Nett, Gregory M. Rose, and F. Edward Dudek, J. Neurosci. 1999, 19(22):10053-10064.
Wenning GK, Granata R, Puschban Z, Scherfler C, Poewe W., .J Neural Transm Suppl. 1999;55:103-13, Medline abstract PMID: 10335497.
Rebecca J. Carter et al ,The Journal of Neuroscience, Apr. 15, 1999, 19(8):3248-3257.
Yanamoto H, Nagata I, Niitsu Y, Xue JH, Zhang Z, Kikuchi H., Evaluation of MCAO stroke models in normotensive rats: standardized neocortical infarction by the 3VO technique, Exp Neurol. Aug. 2003;182(2):261-74.
Osborne NN, Chidlow G, Layton CJ, Wood JP, Casson RJ, Melena J., Optic nerve and neuroprotection strategies.Eye. Nov. 2004;18(11):1075-84.
Jenner, Peter, Expert Opin. Investig. Drugs, 14(6), 2005, pp. 729-738.
(Abstract only) Bailey et al., “Changes in spinal δ- and K-opioid systems in mice deficient in the A2A receptor gene”,Journal of Neuroscience, vol. 22, No. 21, 2002 (pp. 9210-9220).
(Abstract only) Bara-Jimenez et al., “Adenosine A2A receptor antagonist treatment of Parkinson's disease”,Neurology, vol. 61, No. 3, 2003 (pp. 293-296).
Bastia et al., “Effects of A1and A2Aadenosine receptor ligands in mouse acute models of pain”,Neuroscience Letters 328, 2002 (pp. 241-244).
Behan et al., “Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2Areceptor antagonists”,British Hournal of Pharmacology, vol. 135, 2002 (pp. 1435-1442).
Bertorelli et al., “Effects of Selective Agonists and Antagonists for A1or A2AAdenosine Receptors on Sleep-Waking Patterns in Rats”,Drug Development Research, vol. 37, 1996 (pp. 65-72).
(Abstract only) Chase et al., “Translating A2Aantagonist KW6002 from animal models to parkinsonian patients”,Neurology, vol. 61, (11, Suppl. 6), (pp. S107-S111).
Dall'lgna et al., “Neuroprotection by caffeine and adenosine A2Areceptor blockade of β-amyloid neurotoxicity”,British Journal of Pharmacology, vol. 138, 2003 (pp. 1207-1209).
Fredholm, et al., “Actions of Caffeine in the Brain with Special References to Factors That Contribute to Its widespread Use”,Pharmacological Reviews, vol. 51, No. 1, 1999 (pp. 83-133).
Garfinkel, et al., “Responses to Methylphenidate and Varied Doses of Caffeine in Children with Attention Deficit Disorder”,Can. J. Psychiatry, vol. 26, No. 6, Oct. 1981 (pp. 395-401).
González-Benitez et al., “Regulation of glycogen metabolism in hepatocytes through adenosine receptors. Role of Ca2+and cAMP”,European Journal of Pharmacology, vol. 437, 2002 (pp. 105-111).
(Abstract only) Hauser et al., “Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD”,Neurology, vol. 61, No. 3, 2003 (pp. 297-303).
Hess, “Recent advances in adenosine receptor antagonist research”,Review, Monthly Focus: Central and Peripheral Nervous Systems, 2001 (pp. 1533-1561).
Ikeda et al., “Neuroprotection by adenosine A2Areceptor blockade in experimental models of Parkinson's disease”,Journal of Neurochemistry, vol. 80, No. 2, Jan. 2002 (pp. 262-270).
(Abstract only) Kase, “New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia”,Biochemistry, vol. 65, No. 7, 2001 (pp. 1447-1457).
Kopf et al., “Adenosine and memory storage: effect of A1and A2receptor antagonists”,Psychopharmacology, vol. 146, No. 2, Sep. 11, 1999 (pp. 214-219).
(Abstract only) Ledent et al., “Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor”,Nature, vol. 388(6643), Aug. 14, 1997 (pp. 674-678).
Li et al., “Differing Roles of Adenosine Receptor Subtypes in Retinal Ischemia-Reperfusion Injury in the Rat”,Exp. Eye Res., vol. 68, 1999 (pp. 9-17).
Mally et al., “Potential of Adenosine A2AReceptor Antagonists in the Treatment of Movement Disorders”,CNS Drugs, vol. 10, No. 5, Nov. 1998 (pp. 311-320).
Monopoli et al., “Blockade of adenosine A2Areceptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats”,Neuropharmacology, vol. 9, No. 17, Dec. 1, 1998 (pp. 3955-3959).
Monopoli et al., “Cardiovascular Pharmacology of the A2AAdenosine Receptor Antagonist, SCH 58261, in the Rat”,The Journal of Pharmacology and Experimental Therapeutics, vol. 285, No. 1, 1998 (pp. 9-15).
Ongini et al., “Dual Actions of A2AAdenosine Receptor Antagonists on Motor Dysfunction and Neurodegenerative Processes”,Drug Development Research, vol. 52, No. ½, 2001 (pp. 379-386).
Popoli et al., “Blockade of Striatal Adenosine A2AReceptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum”,The Journal of Neuroscience, vol. 22, No. 5, Mar. 1, 2002 (pp. 1967-1975).
Satoh et al., “Involvement of adenosine A2Areceptor in sleep promotion”,European Journal of Pharmacology, vol. 351, 1998 (pp. 155-162).
Scammell et al., “An Adenosine A2a Agonist Increases Sleep and Induces FOS in Ventrolateral Preoptic Neurons”,Neuroscience, vol. 107 No. 4, 2001 (pp. 653-663).
Schechter, M.D. et al.
Bamford Samantha Jayne
Gaur Suneel
Gillespie Roger John
Leonardi Stefania
Lerpiniere Joanne
Berch Mark
Foley & Lardner LLP
Moore Susanna
Vernalis Research Ltd.
LandOfFree
Triazolo[4,5-d]pyrimidine derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolo[4,5-d]pyrimidine derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolo[4,5-d]pyrimidine derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3621157